It is possible that the same reciprocal relationship exists in ovarian cancer and that a similar combination treatment with an AR inhibitor, enzalutamide and a PI3K/AKT pathway inhibitor, metformin, could benefit ovarian cancer patients. This evidence concerns the gene AKT1 and ovarian cancer.